Biological actions of human urotensin II on cardiovascularsystem

Abstract

Abstract: Urotensin II(U-II),a cyclic peptide has been initially identified as a neuropeptide of teleost fish.Subsequently,U-II has been characterized in the brain of the Europeangreen frog and has also been cloned from the human genome.Human U-II(human U-II,hU-II),composed of 11 amino acid residues is rich in cardiovas-cularand nervous system.As an endogenous ligand forUT receptor,hU-II exerts a broad spectrum of biological actions,such as vasoconstriction and vasorelaxation,fa-cilitating proliferation of cardiac cells,regulating the car-diac function and playing an important role in pathogene-sis of some cardiovasculardiseases such as coronary heart disease and cardiac failure.The effects of hU-II on card-iovascularsystem were briefly reviewed as follows.

Key words: human urotensinII, cardiovascularsys-tem, UT receptor, biological actions

CLC Number:

R972

DING Bo, GAO Shan, CHEN Zhi-wu. Biological actions of human urotensin II on cardiovascularsystem[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(11): 1210-1214.

References

1 Conlon JM,Yano K,Waugh D,HazonN.Distribution andmo-lecularformsof urotensin II and its role in cardiovascularregula-tion in vertebrates[J].J ExPZool,1996,275:226-38
2 Behan DP,Khongsaly O,Ling N,De Souza EB.Urocortin inter-action with corticotropin-releasing factor(CRF) binding protein(CRF-BP):a novel mechanism forelevating “free”CRF levels in human brain[J].Brain Res,1996;725:263-7
3 Coulouarn Y,Lihrmann I,Jegou S,AnouarY,Tostivint H,Beauvillain JC,et al.Cloning of the cDNA encoding the uro-tensin II precursorin frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord[J].Proc NatlAcad Sci U S A,1998;95:15803-8
4 mes RS,Sarau HM,Chambers JK,Willette RN,AiyarNV,Ro-manic AM,et al.Human urotensin-II is a potent vasoconstrictorand agonist forthe orphan receptorGPR14[J].Nature,1999;401:282-6
5 Liu Q,Pong SS,Zeng Z,Zhang Q,Howard AD,Williams DL Jr,et al.Identification of urotensin II as the endogenous ligand forthe orphan G-protein-coupled receptorGPR14[J].Biochem Biophys Res Commun,1999;266:174-8
6 Maguire JJ,Kuc RE,Davenport AP.Orphan-receptorligand hu-man urotensin II:receptorlocalization in human tissues and comparison of vasoconstrictorresponseswith endothelin-1[J].BrJ Pharmacol,2000;131:441-6
7 Maclean MR,AlexanderD,Stirrat A,GallagherM,Douglas SA,Ohlstein EH,et al.Contractile responses to human urotensin-II in rat and human pulmonary arteries:effect of endothelial factors and chronic hypoxia in the rat[J].BrJ Pharmacol,2000;130:201-4
8 HillierC,Berry C,Petrie MC,O' DwyerPJ,Hamilton C,Brown A,et al.Effects of urotensin II in human arteries and veins of varying caliber[J].Circulation,2001;103:1378-81
9 Gibson A.Complex effects of Gillichthys urotensin II on rat aort-ic strips[J].BrJ Pharmacol,1987;91:205-12
10 NothackerHP,Wang Z,Mcneill AM.Satio Y,Merten S,O'Dowd B,et al.Identification of the natural ligand of an orphan G-protein-coupled receptorinvolved in the regulation of vasocon-striction[J].Nat Cell Biol,1999;1:383-5
11 Itoh H,McMasterD,Lederis K.Functional receptors forfish neuropeptide urotensin II inmajorrat arteries[J].EurJ Phar-macol,1988;149:61-6
12 Opgaard O,NothackerH,Ehlert FJ,Krause DN.Human uroten-sin II mediates vasoconstriction via an increase in inositol phos-phates[J].EurJ Pharmacol,2000;406:265-71
13 Rossowski WJ,ChengBeng L,TaylorE,Datta R,Coy DH.Hu-man urotensin II-induced aorta ring contractions are mediated by protein kinase C,tyrosine kinases andRho-kinase:inhibition by somatostatin receptorantagonists[J].EurJ Pharmacol,2002;438:159-70
14 Sauzeau V,Le Mellionnec E,Bertoglio J,Scalbert E,Pacaud P,Loirand G,et al.Human Urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-Kinase[J].Circulation Res,2001;88:1102-04
15 Bottrill FE,DouglasSA,Hiley CR,White R.Human urotensin-II is an endothelium-dependent vasodilatorinrat small arteries[J].BrJ Pharmacol,2000;130:1865-70
16 Camarda V,Rizzi A,Calo G,GendronG,PerronSI,Kostenis E,et al.Effects of human urotensin II in isolated vessels of va-rious species;comparison withothervasoactive agents[J].Nau-nyn SchmiedebergsArch Pharmacol,2002;365:141-9
17 Stirrat A,GallagherM,DouglasSA,Ohlstein EH,Berry C,Kirk A,et al.Potent vasodilatorresponses to human urotensin-II in human pulmonary and abdominal resistance arteries[J].Am J Physiol Heart Circ Physiol,2001;280:H925-8
18 GardinerSM,March JE,KemPPA,Davenport AP,Bennett T.Depressorand regionally-selective vasodilatoreffects of human and rat urotensin II in conscious rats[J].BrJPharmacol,2001;132:1625-9
19 Gibson A,Conyears S,Bern HA.The influence of urotensin II on calcium flux in rat aorta[J].J Pharm Pharmacol,1988;40:893-5
20 Gray GA,Jones MR,Sharif I.Human urotensin II increases cor-onary perfusion pressure in the isolated rat heart:potentiation bynitric oxide synthase and cyclooxygenase inhibition[J].Life Sci,2001;69:175-80
21 Lin L,Ding WH,Jiang W,Zhang YG,Qi YF,Yuan WJ,et al.Urotensin-II activates L-arginine nitric oxide pathway in isolated rat aortic adventitia[J].Peptides,2004;25:1977-84
22 Katano Y,Ishihata A,Aita T,Ogaki T,Horie T.Vasodilatoref-fect of urotensin II,one of the most potent vasoconstricting fac-tors,on rat coronary arteries[J].EurJ Pharmacol,2000;402:R5-7
23 White R,Hiley CR.A comparison of EDHF-mediated and anan-damide-induced relaxations in the rat isolated mesenteric artery[J].BrJ Pharmacol,1997;122:1573-84
24 张勇刚,齐永芬,夏春芳,庞永正,杨军,唐朝枢,等.尾加压素 II 血管平滑肌细胞增殖的影响[J].中国药理学通报,2001;17:155-7
25 孙正浩,张孙曦,李菊香,何其华,牛大地,袁杰,等.钙信号在尾加压素 II 促血管平滑肌增殖中的作用[J].北京大学学报(医学版) ,2002;34:261-5
26 Zou Y,Nagai R,Yamazaki T.Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats[J].FEBS Lett,2001;508:57-60
27 Shibata R,Kai H,Seki Y,Kato S,Morimatsu M,KaibuchiK,et al.Role of Rho-associated kinase in neointima formation aftervascularinjury[J].Circulation,2001;103:284-9
28 Tamura K,OkazakiM,TamuraM,IsozumiK,TasakiH,Nakash-ima Y.Urotensin II-induced activation of extracellularsignal -regulated kinase in cultured vascularsmooth muscle cells:in-volvement of cell adhesion-mediated integrin signaling[J].Life Sci,2003;72:1049-60
29 Watanabe T,Pakala R,Katagiri T,Benedict CR.Synergistic ef-fect of urotensin II with mildly oxidized LDL on DNA synthesis invascularsmooth muscle cells[J].Circulation,2001;104:16-8
30 Watanabe T,Pakala R,Katagiri T,Benedict CR.Synergistic ef-fect of urotensin II with serotonin onvascularsmooth muscle cell proliferation[J].J Hypertens,2001;19:2191-6
31 Watanabe T,Koba S,Katagiri T,Pakala R,Benedict CR.Lyso-phosphatidylcholine potentiates the mitogenic effect of various vasoactive compounds on rabbit aortic smooth muscle cells[J].Jpn Heart J,2002;43:409-16
32 TzanidisA,Hannan RD,Thomas WG,Onan D,Autelitano DJ,See F,et al.Direct actions of urotensin II on the heart:impli-cations forcardiac fibrosis and hypertrophy[J].Circ Res,2003;93:246-53
33 Le Mevel JC,Olson KR,Conklin D,Waugh D,Smith DD,Vaudry H,et al.Cardiovascularactions of trout urotensin II in the conscious trout,Oncorhynchus mykiss[J].Am J Physiol,1996;271:R1335-43
34 Russell FD,MolenaarP,O' Brien DM.Cardiostimulant effects of urotensin-II in human heart in vitro[J].BrJ Pharmacol,2001;132:5-9
35 Richards AM,NichollsMG,Lainchbury JG,FisherS,Richards AM.Plasma urotensin II in heart failure[J].Lancet,2002;360:545-6
36 钟萍,李志梁,吴宏超,唐朝枢,陆青.心力衰竭患者血浆尾加压素 II 与肾上腺髓质素片段的关系[J].第四军医大学学报,2003;24:1603-05
37 Dschietzig T,Bartsch C,Pregla R,Zurbrugg HR,ArmbrusterFP,RichterC,et al.Plasma levels and cardiovasculargene ex-pressionof urotensin-II in human heart failure[J].Regul Pept,2002;110:33-8
38 刘秀华,蔡莉蓉,唐朝枢,武旭东,刘凤英,苏静怡.尾加压素预处理对大鼠心脏缺血再灌注损伤的影响[J].中国病理生理杂志,2003;19:1456-58
39 GendronG,Simard B,Gobeil F Jr,Sirois P,D' Orleans-Juste P,Regoli D.Human urotensin-II enhances plasma extravasation in specific vasculardistricts inWistarrats[J].Can J Physiol Phar-macol,2004;82:16-21

[1]	CHEN Xi, LI Yongjun. Effects of Chinese patent medicine for activating blood circulation on cardiac repair after myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 680-688.
[2]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[3]	YUAN Zhen, CHEN Bilian. Review of bleeding events in clinical studies of clopidogrel [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 341-349.
[4]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[5]	DANG Xiangji, ZHOU Lin, WANG Yixuan, ZENG Lu. Individualized antithrombotic therapy on one patient with chronic renal insufficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 477-480.
[6]	PU Chun, TAO Qingsong, ZHU Xiang, QIN Mingming, WU Qiwen, FENG Gang. Value of three cardiac markers in the early diagnosis of acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 82-86.
[7]	JIANG Peng-li, WU Jing, SUN He. Association of cognitive decline, diabetes mellitus and cancer with statins use: gaining insight through the FDA pharmacovigilance database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1132-1138.
[8]	WANG Pan, XIE Shan-shan, GUO Jian-jun, BU Hai-zhi, CHEN Xi-jing. Research overview in absorption, distribution, metabolism and excretion of dihydropyridine calcium antagonists [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 937-943.
[9]	WANG Zhen-shan, LI Ling, DENG Xiao-lan, LI Hui, YU Min, YAN Jin, CHEN Ben-mei, YANG Guo-ping, OU-YANG Dong-sheng. LC-MS determination of terazosin in human plasma and application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(5): 530-534.
[10]	ZHANG Hong-xia, WU Yong-jie, GAO Ming-tang. Protective effects of DDPH on myocardial ischemia reperfusion injury in isolated rat hearts [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 160-165.
[11]	WANG Zhan-qing, WANG Jin-ping, XU Jing-feng. Isosorbide dinitrate induces late preconditioning against myocardial infarction in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(12): 1385-1388.
[12]	ZHU Shen-yin, ZHOU Yuan-da, DU Guan-hua. Research progress of xanthine oxidoreductase in biological functions and its inhibitor development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1081-1086.
[13]	XUE Hao, GAO Min, LIU Guo-shu, WANG Hai. Effect of iptakalim hydrochloride on extracellular matrix of kidney in spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1122-1128.
[14]	WANG Zhan-qing, YING Xiang-yu, XU Jing-feng. Advances in preclinical studies on combination therapy of myocardial ischemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(8): 847-850.
[15]	YU Shuang, YU Li-mei, YUAN Mu, YU Hong, WU Qin, SHI Jin-shan. Effect of naftopidil'ramification-BWYJ on benign prostatic hyperplasia in mice and rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(8): 873-877.